BriaCell Appoints Martin Schmieg to Board of Directors
December 01 2020 - 05:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a
clinical-stage biotechnology company specializing in targeted
immunotherapy for advanced breast cancer, is pleased to announce
that Mr. Martin Schmieg has rejoined the Company as a member of its
Board of Directors.
Having previously served as a member of
BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a
“C” level executive with a diversified background in the global
biotech, med-tech and pharmaceutical industries with 40 years of
business experience. He currently serves as Co-Founder and CEO of
ClearIt, LLC., a private company based in Massachusetts. As a
hands-on leader, Mr. Schmieg’s early career focused on accounting
and financial management responsibilities serving as Chief
Financial Officer to privately held Cytometrics, Inc., Advanced
Bionics Corporation and publicly traded Sirna Therapeutics, Inc.
and Isolagen, Inc. With Cytometrics, he raised $55 million in four
rounds of venture capital financing to bring the company’s
Cytoscan® instrument to market. With Advanced Bionics, he was the
financial architect of the company’s sale to Boston Scientific
(BSX) for $4.2 billion. With Sirna Therapeutics and in
collaboration with its venture owners, he co-developed the
company’s strategic plan which led to the company’s acquisition by
Merck & Co for $1.3 billion.
In 2006, Mr. Schmieg assumed the position of
Chief Executive Office of Freedom-2, Inc., a venture startup in
novel dermatology applications. While at Freedom-2, Mr. Schmieg
raised $14 million in venture capital and led the company in the
development and market introduction of InfinitInk®, which was a
Time Magazine “Invention of the Year” in 2008. In 2009, Mr. Schmieg
reversed merged Freedom-2 into Nuvilex, Inc., now PharmaCyte,
Inc.
Since 2010, Mr. Schmieg has been providing
strategic advisory services to the life sciences industry including
engagements with the following companies: NeoStem, Inc. (now
Caladrius Biosciences, Inc.), Beckman Coulter Genomics, Calimmune,
Inc., Cryoport, Inc., Sapientia Pharmaceuticals, Inc. and Rokk3r
Labs, LLC. Martin holds a BS from LaSalle University, Philadelphia,
PA and is a certified public accountant.
“We are pleased to welcome back Martin, a
biotech veteran, to our Board,” remarked BriaCell CEO Dr. Bill
Williams. “Martin’s unique experience in the industry will be an
asset to us as we are expanding our reach in the industry to
identify and evaluate strategic partnership opportunities.”
“I am extremely excited to be rejoining the
BriaCell Board,” noted Mr. Schmieg. “I look forward to again
working closely with my BriaCell colleagues to support efforts to
advance its pipeline of product candidates and prospective
corporate partners.”
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding
Forward-Looking Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2023 to Mar 2024